pharma · Chronic Spontaneous Urticaria · Asthma
Novartis India
Novartis Pharmaceuticals
Novartis Pharmaceuticals is a pharma organization headquartered in CN. Primary therapeutic focus areas include Chronic Spontaneous Urticaria, Asthma, Systemic Lupus Erythematosus, Breast Cancer, Multiple Sclerosis. NovaP
Mumbai, IN HQ
1996 Founded
2,240 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- Mumbai, IN
- Founded
- 1996
- Employees
- 2,240
- Programs
- 341
- Drugs
- 317
- Patents
- 0
Kesimpta 20 mg solution for injection in pre-filled syringe
Approved · small molecule · Relapsing forms of Multiple Sclerosis (RMS)
Kesimpta 20 mg solution for injection in pre-filled syringe for Relapsing forms of Multiple Sclerosis (RMS) is a Approved program (small_molecule) at Novartis Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Internal code COMB157G2410
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Novartis Pharmaceuticals
- Phase
- Approved
- Modality
- small_molecule
- Indication
- Relapsing forms of Multiple Sclerosis (RMS)
- Status
- active
- Trials
- 1